Should You Buy This Biotech Stock Near Its 52-Week Low?

: CMRA | Comera Life Sciences Holdings, Inc. News, Ratings, and Charts

CMRA – Recently listed biotech stock Comera Life Sciences is trading near its 52-week low. The stock is down more than 75% year-to-date. Although the $15 million purchase agreement with Arena Business Solutions is expected to help it invest in its product pipeline and formulation platform SQore, will it be wise to invest in the stock given its weak financials, stretched valuation, and weak profitability? Read on to learn our view….

Biotech stocks attracted investors’ attention last year due to their role in developing vaccines and therapies to save the world from the COVID-19 pandemic. However, several industry participants have delivered disappointing stock market performance this year due to uncertain macroeconomic conditions.

Earlier this year, biologics company ReForm Biologics, Inc. renamed itself Comera Life Sciences Holdings, Inc. (CMRA - Get Rating).

On January 31, 2022, CMRA and special purpose acquisition company OTR Acquisition Corp. (OTRAU) announced that they had entered into a business combination agreement through which CMRA would get access to the equity markets.

CMRA is a pre-clinical biotechnology company. The company is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. Its proprietary formulation platform, SQore, is designed to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose.

The platform optimizes current versions of subcutaneous biologics and produces biosimilar versions of existing subcutaneous products.

The stock has declined 75.5% in price year-to-date and 75.3% over the past year to close the last trading session at $2.48. It is trading 83.8% below its 52-week high of $15.30, which it hit on May 10, 2022.

Here’s what could influence CMRA’s performance in the upcoming months:

Weak Financials

CMRA’s total operating expenses increased 93.3% year-over-year to $3.70 million for the second quarter ended June 30, 2022. Its loss from operations widened 89.8% year-over-year to $3.61 million. In addition, its net loss widened 368.9% year-over-year to $9.28 million. The company’s loss per share widened 67.6% year-over-year to $1.14.

Stretched Valuation

In terms of trailing-12-month EV/S, CMRA’s 116.97x is significantly higher than the 4.21x industry average. Likewise, its 19.63x trailing-12-month P/S is 331% higher than the 4.55x industry average.

Weak Profitability

CMRA’s 53.77% trailing-12-month gross profit margin is 1% lower than the 54.31% industry average. Likewise, its 0.08% trailing-12-month asset turnover ratio is 76.6% lower than the industry average of 0.34%.

POWR Ratings Reflect Bleak Prospects

CMRA has an overall D rating, equating to Sell in our POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. CMRA has a D grade for Value, in sync with its stretched valuation. It also has a D grade for Quality, consistent with its weak profitability.

CMRA is ranked #374 out of 400 stocks in the F-rated Biotech industry. Click here to access CMRA’s ratings for Growth, Momentum, Stability, and Sentiment.

Bottom Line

CMRA entered into a purchase agreement with Arena Business Solutions for $15 million of the company’s common stock with an option to increase to $30 million. This will enable the company to invest in its product pipeline and strengthen its formulation platform, SQore. The agreement should bolster its balance sheet and help it achieve its near-term objectives.

Despite the agreement, the company might take significant time to turn profitable. Given its weak financials, stretched valuation, and weak profitability, it could be wise to avoid the stock now.

How Does Comera Life Sciences Holdings, Inc. (CMRA) Stack Up Against Its Peers?

CMRA has an overall POWR Rating of D, equating to a Sell rating. Therefore, one might want to consider investing in other Biotech stocks with an A (Strong Buy) or B (Buy) rating, such as Vertex Pharmaceuticals Incorporated (VRTX - Get Rating), Biogen Inc. (BIIB - Get Rating), and Genfit S.A. (GNFT - Get Rating).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


CMRA shares were trading at $2.19 per share on Monday morning, down $0.29 (-11.69%). Year-to-date, CMRA has declined -75.25%, versus a -18.21% rise in the benchmark S&P 500 index during the same period.


About the Author: Dipanjan Banchur


Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CMRAGet RatingGet RatingGet Rating
VRTXGet RatingGet RatingGet Rating
BIIBGet RatingGet RatingGet Rating
GNFTGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Bear or Bull Market?

The S&P 500 is on the brink of bear market territory...but that outcome is not a given at this time. Steve Reitmeister shares insights gleaned from his 45 years of investing to shine a light on current conditions along with his top picks...

Read More Stories

More Comera Life Sciences Holdings, Inc. (CMRA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CMRA News